[
    "{\"step_by_step_thinking\": \"Mogamulizumab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets CC chemokine receptor 4 (CCR4). It has shown promising therapeutic potential in phase I and II clinical trials and is currently being investigated for efficacy in treating cutaneous T-cell lymphoma (CTCL). The documents also mention that the FDA has approved mogamulizumab for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or S\u00e9zary syndrome (SS) who have been treated with at least one prior line of therapy. Therefore, mogamulizumab can be used for the treatment of cutaneous T-cell lymphoma.\", \"answer_choice\": \"A\"}"
]